We claim:

1. A pharmaceutical composition comprising: Palmitoylethanolamide (PEA) and at least one naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitor, wherein the naturally occurring FAAH Inhibitor is selected from the group consisting of: Myricetin, Isorhamnetin, Kaempferol, Biochanin A, Genistein, Daidzein and a combination thereof.

2. The pharmaceutical composition as claimed in claim 1, wherein the amount of PEA is in a range of 35% to 80% by weight of the pharmaceutical composition.

3. The pharmaceutical composition as claimed in claim 1, wherein the amount of naturally occurring FAAH Inhibitor is in a range of 0.5% to 40% by weight of the pharmaceutical composition.

4. The pharmaceutical composition as claimed in claim 1, wherein the naturally occurring FAAH Inhibitor is selected from the group consisting of: Daidzein, Genistein, and a combination thereof.

5. The pharmaceutical composition as claimed in any one of claims 1 to 4, wherein the pharmaceutical composition further comprises at least one of: vitamins, coenzymes and a combination thereof.

6. The pharmaceutical composition as claimed in claim 5, wherein the vitamins are selected from the group consisting of: methylcobalamin, cyanocobalamin, benfotiamine and a combination thereof; and wherein the coenzymes are selected from the group consisting of: ubidecarenone, thiamine pyrophosphate, Flavin adenine dinucleotide and a combination thereof.

7. The pharmaceutical composition as claimed in claim 5, wherein an amount of the vitamins is in a range of 0.01% to 30% by weight of the pharmaceutical composition.

8. The pharmaceutical composition as claimed in claim 5, wherein an amount of the co-enzymes is in a range of 10% to 40% by weight of the pharmaceutical composition.

9. The pharmaceutical composition as claimed in any one of claims 1 to 8, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

10. The pharmaceutical composition as claimed in claim 9, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of a diluent, a disintegrant, a binder, a solubilizing agent, a lubricant, a glidant, a solvent and a combination thereof.

11. The pharmaceutical composition as claimed in claim 10, wherein, when present,

- an amount of the diluent is in a range of 5% to 50% by weight of the pharmaceutical composition,
- an amount of the disintegrant is in a range of 0.5% to 10 % by weight of the pharmaceutical composition,
- an amount of the binder is in a range of 0.1% to 10% by weight of the pharmaceutical composition,
- an amount of the solubilizing agent is in a range of 0.25% to 15% by weight of the pharmaceutical composition,
- an amount of the lubricant is in a range of 1.0% to 10% by weight of the pharmaceutical composition
- an amount of the glidant is in a range of 1.0% to 10% by weight of the pharmaceutical composition, and
- an amount of the solvent is quantity sufficient.

12. The pharmaceutical composition as claimed in claim 1, wherein the pharmaceutical composition is in the form selected from the group consisting of: a tablet, a capsule, a sachet, a pill, a hard capsule filled with liquid, a hard capsule filled with solids, a soft capsule, a powder, a granule, a suspension solution and a modified release formulation.

13. A process for preparing a pharmaceutical composition as claimed in claim 1, the process comprising:

a) weighing accurately Palmitoylethanolamide (PEA), the at least one naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitor, at least one diluent, and at least one disintegrating agent in separate containers;

b) sifting previously weighed PEA, the at least one naturally occurring FAAH Inhibitor, the at least one diluent, and the at least one disintegrating agent separately;

c) mixing content of step b);

d) preparing a binder solution in a separate container and add the binder solution to step c) to provide a dough, and sieve the dough to obtain granules;

e) drying the obtained granulates until the level of dryness (LOD) is reduced to less than 1.5 % w/w;

f) sifting semi dried granules from step e) through a sieve;

g) sifting one of: at least one previously weighed lubricant and at least one previously weighed glidant, separately through the sieve and add to step f).